Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications.

The $4.22 (76%) decline to $1.33 for CymaBay Therapeutics Inc. (NASDAQ:CBAY) follows the company's 45% decline on June 11 due to the

Read the full 520 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE